20/20 Biolabs, Inc. SEC filings AIDX

20/20 Biolabs, Inc. has 167 filings in SEC EDGAR's recent list, going back to Jan 18, 2002. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 18, 2026 (shareholder vote results). The company's fiscal year ends on December 31.

20/20 Biolabs, Inc. SEC filings
Form Description Filed Period
424B3 Prospectus Aug 17, 2026 —
424B3 Prospectus Aug 17, 2026 —
424B3 Prospectus May 21, 2026 —
424B3 Prospectus May 21, 2026 —
424B3 Prospectus Apr 28, 2026 —
424B3 Prospectus Apr 28, 2026 —
424B3 Prospectus Apr 13, 2026 —
424B3 Prospectus Apr 13, 2026 —
S-1 Registration statement Apr 6, 2026 —
POS AM Post-effective amendment no. 1 to form s-1 Apr 6, 2026 —
424B3 Prospectus Feb 18, 2026 —
S-1/A Amended registration statement Jan 26, 2026 —
S-1/A Amended registration statement Jan 21, 2026 —
S-1 Registration statement Dec 12, 2025 —

Showing 14 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Services-Testing Laboratories (SIC 8734)
Listed as
AIDX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Rockville, MD
SEC filer status
, Emerging growth company
SEC CIK
1139685
Former names
20/20 GeneSystems, Inc. (until Feb 26, 2025); 20/20 GENE SYSTEMS INC (until Apr 28, 2004)

Other Services-Testing Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.